Abstract
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody indicated for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS), targeting the CD52 glycoprotein expressed on the surface of immune cells, mainly T a B lymphocytes. The precise action of alemtuzumab is unknouwn, but it is thought to involve binding with CD52 antigen that leads to depletion of circulating T and B cells resulting in development of new lymphocyte generation potentially without autoaggressive sings of the original population.
Although the efficacy of alemtuzumab has been widely proven, several severe adverse effects have been reported with its use. In this paper we describe the first and successfully alemtuzumab-treated MS patient in our department.